Johnson & Johnson Is Walking Away From a $100 Billion Obesity Market. Could That Actually Make It the Better Long-Term Buy Than Eli Lilly?
Key Points Johnson & Johnson’s CEO recently explained that his company isn’t going to get caught up in the GLP-1…